Inside Precision Medicine January 2, 2025
Researchers at Genentech and Stanford University have found 776 genomic alterations linked to survival outcomes across 20 cancer types with specific immunotherapies, chemotherapies, or targeted therapies. The team carried out a comprehensive analysis of 78,287 U.S. cancer patients with detailed somatic mutation profiling integrated with treatment and outcomes data extracted from electronic health records.
They also used the data to create a machine learning model to predict response to immunotherapy in one type of lung cancer.
“Additionally, we demonstrate how mutations in particular pathways correlate with treatment response,” they wrote.
Their study appears in Nature Communications and was led by Ruishan Liu, PhD, department of electrical engineering, Stanford.
They added, “The adoption of next-generation sequencing (NGS) has revolutionized genomics profiling,...
Today's Sponsors
Today's Sponsor